Alpha-synuclein preformed fibrils:a tool to understand Parkinson’s disease and develop disease modifying therapy  

作　　者：Piotr Chmielarz Andrii Domanskyi 

机构地区：[1]Institute of Biotechnology,HiLIFE,University of Helsinki,Finland [2]Maj Institute of Pharmacology,Polish Academy of Sciences,Department of Brain Biochemistry,Kraków,Poland [3]Orion Corporation Orion Pharma,Turku,Finland

出　　处：《Neural Regeneration Research》2021年第11期2219-2221,共3页中国神经再生研究（英文版）

基　　金：supported by grants from the Academy of Finland#293392,#319195;Päivikki and Sakari Sohlberg Foundation(to AD);Polish National Science Centre grant 2019/35/D/NZ7/03200-Sonata 15(to PC).

摘　　要：Parkinson’s disease(PD)is the second most common neurodegenerative disorder characterized by multiple motor and nonmotor symptoms,which include,among others,constipation,sleep disturbance,bradykinesia,gait and balance abnormalities,muscle stiffness and resting tremor.The motor symptoms are caused by progressive age-related death of dopaminergic neurons and in the vast majority of patients suffering from age-related idiopathic PD the cause of dopaminergic neurodegeneration is unknown.Even in the familial early-onset PD where genetic mutations have been identified,the molecular mechanisms driving degeneration of dopaminergic neurons are far from clear.Consequently,there is no clinically approved disease-modifying therapy capable of stopping or at least slowing down the disease progression.

关 键 词：degeneration Alpha driving 

分 类 号：R742.5[医药卫生—神经病学与精神病学]